INFLARX NV (IFRX) Stock Price, Forecast & Analysis
USA - NASDAQ:IFRX - NL0012661870 - Common Stock
IFRX Key Statistics, Chart & Performance
The current stock price of IFRX is 1.35 USD. In the past month the price increased by 14.41%. In the past year, price decreased by -30.77%.
IFRX Latest News, Press Relases and Analysis
IFRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About IFRX
Company Profile
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 74 full-time employees. The company went IPO on 2017-11-08. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
Company Info
INFLARX NV
Winzerlaer Str. 2
Jena THUERINGEN 07745 DE
CEO: Niels Riedemann
Employees: 74
Phone: 493641508180
INFLARX NV / IFRX FAQ
Can you describe the business of INFLARX NV?
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 74 full-time employees. The company went IPO on 2017-11-08. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
What is the current price of IFRX stock?
The current stock price of IFRX is 1.35 USD. The price increased by 6.3% in the last trading session.
What is the dividend status of INFLARX NV?
IFRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of IFRX stock?
IFRX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the next earnings date for IFRX stock?
INFLARX NV (IFRX) will report earnings on 2026-03-18, after the market close.
Who owns INFLARX NV?
You can find the ownership structure of INFLARX NV (IFRX) on the Ownership tab.
IFRX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to IFRX. When comparing the yearly performance of all stocks, IFRX is one of the better performing stocks in the market, outperforming 76.52% of all stocks.
IFRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IFRX. IFRX may be in some trouble as it scores bad on both profitability and health.
IFRX Financial Highlights
Over the last trailing twelve months IFRX reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS increased by 11.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.67% | ||
| ROE | -79.4% | ||
| Debt/Equity | 0 |
IFRX Forecast & Estimates
14 analysts have analysed IFRX and the average price target is 4.23 USD. This implies a price increase of 213.02% is expected in the next year compared to the current price of 1.35.
For the next year, analysts expect an EPS growth of 15.34% and a revenue growth -74.12% for IFRX